Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while YieldMax Universe Fund of Option Income ETFs trades at $7.85. Which is the better fit depends on your goals.
| ALNY | YMAX | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $14.00 |
52-Week Low | $278.09 | $7.51 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
YMAX trades at $7.92, down 0.75% today, with technical indicators showing a neutral to bearish bias. The ETF maintains a consistent weekly dividend distribution strategy, though key valuation and profitability metrics remain unavailable. Recent news highlights the fund's focus on generating income through covered call strategies on a portfolio of YieldMax ETFs.
The outlook centers on YMAX's high distribution yield strategy, which faces headwinds from the bearish moving average signal and market volatility dependence. Investment appeal lies in income generation, but risks include the fund's complex options strategy and expense ratio of 1.33%, with most distributions representing return of capital rather than earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
